There are 91 resources available
Recurrence Post-Radical Resection: Are Systemic Therapies the Solution to Optimize Patient Outcomes?
Presenter: Andrea Necchi
Session: Bristol Myers Squibb - Latest advances in Muscle Invasive Urothelial Carcinoma: How Will They Impact Our Daily Practice?
Resources:
Webcast
Biomarkers: Are We Ready to Use Them in Routine Clinical Practice?
Presenter: Matthew Galsky
Session: Bristol Myers Squibb - Latest advances in Muscle Invasive Urothelial Carcinoma: How Will They Impact Our Daily Practice?
Resources:
Webcast
QoL: Is It a Key Endpoint in the Adjuvant Setting?
Presenter: Matthew Galsky
Session: Bristol Myers Squibb - Latest advances in Muscle Invasive Urothelial Carcinoma: How Will They Impact Our Daily Practice?
Resources:
Webcast
Clinical Cases Discussion (Cisplatin-eligible case; Cisplatin-ineligible case)
Presenter: Matthew Galsky
Session: Bristol Myers Squibb - Latest advances in Muscle Invasive Urothelial Carcinoma: How Will They Impact Our Daily Practice?
Resources:
Webcast
Live Q&A session
Presenter: James Catto
Session: Bristol Myers Squibb - Latest advances in Muscle Invasive Urothelial Carcinoma: How Will They Impact Our Daily Practice?
Resources:
Webcast
Full session recording
Presenter: Nicoletta Colombo
Session: AstraZeneca - Redefining long-term outcomes in newly diagnosed advanced ovarian cancer: Expert perspectives on integrating personalized medicine
Resources:
Webcast
Is a one size fits all approach still appropriate for NSCLS with an EGFR mutation, are all mutations equal?
Presenter: Joachim Aerts
Session: Lilly - Personalising and optimising treatment for metastatic NSCLC patients with EGFR and other co-occurring mutations
Resources:
Webcast
Scientific rationale for dual inhibition of VEGF and EGFR
Presenter: Nobuyuki Takakura
Session: Lilly - Personalising and optimising treatment for metastatic NSCLC patients with EGFR and other co-occurring mutations
Resources:
Webcast
Identifying the clinical and disease characteristics of the high risk patient, what is the science telling us?
Presenter: Federico Cappuzzo
Session: Lilly - Personalising and optimising treatment for metastatic NSCLC patients with EGFR and other co-occurring mutations
Resources:
Webcast
Case study from the clinic – Potential patient profile and include sequencing and discuss with panel
Presenter: Chao-Hua Chiu
Session: Lilly - Personalising and optimising treatment for metastatic NSCLC patients with EGFR and other co-occurring mutations
Resources:
Webcast